BeyondSpring (BYSI) Earns “Buy” Rating from Maxim Group

Maxim Group reissued their buy rating on shares of BeyondSpring (NASDAQ:BYSI) in a report published on Thursday morning. The firm currently has a $52.00 price objective on the stock.

“BeyondSpring will be presenting P2 data (N=55) from study 105 comparing lead asset plinabulin to Neulasta on incidence of neutropenia. The data (detailed below) demonstrates that a single dose of Plinabulin protects against neutropenia at the same rate as Neulasta while producing lower rates of bone pain.”,” the firm’s analyst commented.

A number of other equities research analysts have also issued reports on BYSI. ValuEngine upgraded BeyondSpring from a sell rating to a hold rating in a research report on Wednesday, May 2nd. Zacks Investment Research upgraded BeyondSpring from a hold rating to a buy rating and set a $30.00 price target for the company in a research report on Thursday, April 5th. Finally, HC Wainwright set a $60.00 price objective on BeyondSpring and gave the company a buy rating in a report on Tuesday, April 3rd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $49.60.

BYSI stock opened at $27.38 on Thursday. BeyondSpring has a 1 year low of $19.55 and a 1 year high of $48.49.

BeyondSpring (NASDAQ:BYSI) last posted its quarterly earnings results on Tuesday, April 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.06). sell-side analysts anticipate that BeyondSpring will post -2.8 EPS for the current fiscal year.

BeyondSpring Company Profile

BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.

Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with's FREE daily email newsletter.

Leave a Reply